Company Research Report: Resistell AG
Company Overview
Name
Resistell AG
Mission
Resistell aims to address the challenge of antimicrobial resistance by developing ultra-rapid diagnostic solutions that save lives through timely antibiotic treatment selection.
Founding Details
- Founded Year: 2018
- Founders: Co-founded as a spin-off from École Polytechnique Fédérale de Lausanne (EPFL).
Key People
- Dr. Danuta Cichocka: CEO, Co-Founder, Board Member
- Grzegorz Gonciarz: COO
- Dr. Alex Sturm: Chief Scientific Officer
- Martin Birk: CFO
- Board Members:
- Barbara Staehelin (Chairperson)
- Dr. Federico Buersgens
- Dr. Dieter Kraft
- Trevor Hawkins
- Scientific Advisory Board Members:
- Prof. Dr. Gilbert Greub
- Prof. Dr. Rafael Cantón
- Prof. Giovanni Dietler (Inventor, Co-Founder)
- Dr. Sandor Kasas (Inventor, Co-Founder)
Headquarters
Hofackerstrasse 40, 4132 Muttenz, Switzerland
Number of Employees
No information is available.
Revenue
No information is available.
Company Focus
Resistell is known for its rapid phenotypic antibiotic susceptibility testing (AST) platforms leveraging nanomotion technology to combat antibiotic resistance. Their technology is recognized for significantly reducing the time needed to determine effective antibiotic treatment.
Products
1. Phenotech Multistar
- Description: The fastest Antibiotic Susceptibility Testing (AST) platform offering results in two hours.
- Key Features:
- Growth-independent detection using nanomotion technology.
- Fixed time-to-result of exactly 2 hours.
- Simultaneous analysis of multiple drugs.
- Modularity allows for up to 12 simultaneous patient sample analyses.
- Compatible with existing diagnostic laboratory workflows.
- Equipped with dedicated data analysis software and a user-friendly interface.
2. Phenotech Research
- Description: A platform providing new insights into cellular health and functioning by measuring nanoscale vibrations.
- Key Features:
- Independent of growth or reporter systems.
- Real-time monitoring through high-frequency measurements.
- Non-disruptive analysis not requiring molecular reporters.
- Applicable to various microbes including Gram-negative and positive bacteria, fungi, and yeast.
- Automated sample preparation and data processing.
Recent Developments
New Products and Features
- Launch of the Phenotech Multistar platform offering unprecedented speed in AST.
- Development of Phenotech-CF in collaboration with Lausanne University Hospital and Cellectric, aimed at revolutionizing antimicrobial delivery to cystic fibrosis patients.
Partnerships
- Partnership with Innovative Medicines for Tuberculosis (iM4TB) for the investigation of TB drug candidate, macozinone.
- Collaboration with Cellectric and Lausanne University Hospital under a joint Eurostars project.
Key Personnel Developments
- Appointment of Trevor Hawkins to the Board of Directors.
Recent Recognitions
- Ranked among the Top 10 best start-ups by the TOP 100 Swiss Startup Award, 2023.
- Peer-reviewed publication in Nature Communications detailing their AST platform.
Publications and Research
- Numerous scientific publications including in reputable journals like Nature Communications, specifically on nanomotion technology applications for antibiotic susceptibility testing.
- Research extends to exploration in areas like bloodstream infections, TB, and cystic fibrosis.
Conclusion
Resistell AG continues to innovate in the field of antibiotic susceptibility testing, pushing boundaries with their cutting-edge technology platforms. Their strategic partnerships, technology validation studies, and adaptive approaches mark significant advancements in tackling global antimicrobial resistance challenges.
With ongoing research and collaborative projects, Resistell stays committed to leading healthcare innovation and improving patient outcomes worldwide.
